Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1970 1
1972 1
1976 2
1977 2
1978 3
1979 2
1980 1
1982 1
1983 5
1984 1
1985 2
1986 6
1987 3
1988 1
1989 2
1990 2
1991 1
1992 2
1993 2
1994 5
1995 3
1996 4
1997 2
1998 4
2000 3
2001 3
2002 3
2003 4
2005 4
2006 5
2007 5
2008 3
2009 6
2010 12
2011 10
2012 16
2013 10
2014 6
2015 7
2016 2
2017 4
2018 4
2019 3
2020 3
2021 1
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP. Vincenti F, et al. Among authors: massari p. Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x. Am J Transplant. 2010. PMID: 20415897 Free article. Clinical Trial.
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators. Pascual J, et al. J Am Soc Nephrol. 2018 Jul;29(7):1979-1991. doi: 10.1681/ASN.2018010009. Epub 2018 May 11. J Am Soc Nephrol. 2018. PMID: 29752413 Free PMC article. Clinical Trial.
Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J; TRANSFORM investigators. Berger SP, et al. Among authors: massari p. Am J Transplant. 2019 Nov;19(11):3018-3034. doi: 10.1111/ajt.15480. Epub 2019 Jul 1. Am J Transplant. 2019. PMID: 31152476 Free article. Clinical Trial.
Renal transplantation in high cardiovascular risk patients.
Bittar J, Arenas P, Chiurchiu C, de la Fuente J, de Arteaga J, Douthat W, Massari PU. Bittar J, et al. Among authors: massari pu. Transplant Rev (Orlando). 2009 Oct;23(4):224-34. doi: 10.1016/j.trre.2009.02.001. Epub 2009 Jun 11. Transplant Rev (Orlando). 2009. PMID: 19520563 Review.
164 results